Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 7, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
09:23

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

Hyperleukocytosis from arsenic trioxide.

Michael Levy1, Marcia M Wofford, Bayard L Powell

  • 1Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Pediatric Blood & Cancer
|February 27, 2008
PubMed
Summary

Arsenic trioxide effectively treated a child with recurrent acute promyelocytic leukemia. Hyperleukocytosis resolved during treatment, suggesting it may not require additional therapies.

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Reframing Professionalism Around Trustworthiness: A Practical Approach to Professionalism Curriculum Development.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid Leukemia.

bioRxiv : the preprint server for biology·2025
Same author

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).

Leukemia·2025
Same author

Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia.

Blood advances·2025

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Pharmacology

Background:

  • Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia.
  • Recurrent APL presents unique treatment challenges in pediatric patients.
  • Arsenic trioxide is an established therapy for APL.

Observation:

  • A 14-year-old male with recurrent APL was treated with arsenic trioxide.
  • The patient developed significant hyperleukocytosis (WBC 111.6 x 10(9)/L) during therapy.
  • The hyperleukocytosis resolved spontaneously while arsenic trioxide treatment continued.

Findings:

  • Hyperleukocytosis in pediatric APL patients treated with arsenic trioxide may resolve without intervention.
  • Elevated white blood cell counts during arsenic trioxide therapy do not necessarily indicate treatment failure.

Related Experiment Videos

Last Updated: Jul 7, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
09:23

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

  • Continued arsenic trioxide administration was effective despite initial hyperleukocytosis.

    • Implications:

    • Hyperleukocytosis alone may not warrant additional cytotoxic or steroid therapy in pediatric APL.
    • Discontinuation of arsenic trioxide therapy is likely unnecessary for hyperleukocytosis in this context.
    • This case informs management strategies for pediatric acute promyelocytic leukemia during arsenic trioxide treatment.